Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17293
Country/Region: Tanzania
Year: 2017
Main Partner: Management and Development for Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $15,098,193 Additional Pipeline Funding: $11,067,460

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,430,165
Care: TB/HIV (HVTB) $802,435
Care: Pediatric Care and Support (PDCS) $36,906
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $771,540
Testing: HIV Testing and Counseling (HVCT) $168,561
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $210,141
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $182,341
Treatment: Adult Treatment (HTXS) $9,332,712
Treatment: Pediatric Treatment (PDTX) $1,163,392
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 1,727
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 851
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 1,568
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 771
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 2,495
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 1,247
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 1,919
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 949
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 1,458
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 718
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 1,408
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 686
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 1,169
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 590
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 957
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 466
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 1,388
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 682
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 1,161
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 567
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 160
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 72
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 129
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2018 61
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 15,614
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 7,722
GEND_GBV Number of people receiving post-GBV care 2018 23,342
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 1,407,600
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 82,219
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 9,184
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 12,186
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 16,026
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 10,739
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 19,718
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 22,922
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 47,567
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 34,236
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 6,870
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 5,895
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 2,710
HTS_TST Service Delivery Point (Facility) VMMC: <15, Negative 2018 45,775
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 5,161
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative 2018 6,645
HTS_TST Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative 2018 4,432
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 10,114
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 6,739
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative 2018 203,947
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative 2018 9,971
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative 2018 6,648
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 81,250
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 70,795
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 353,802
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 239,302
HTS_TST Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative 2018 35,505
HTS_TST Sum of Test Result disaggregates 2018 53,973
HTS_TST_POS By Test Result: Positive 2018 53,973
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 750
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 198
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 152
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 404
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 125
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 1,460
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 610
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 6,501
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 2,728
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 1,007
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 989
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 53
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive 2018 130
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive 2018 86
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 218
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 145
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive 2018 7,418
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive 2018 196
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive 2018 130
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 839
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 782
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 17,730
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 9,385
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive 2018 888
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive 2018 698
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2018 3,607
KP_MAT Sex: Female 2018 722
KP_MAT Sex: Male 2018 2,885
KP_MAT Sum of Sex disaggregates 2018 3,607
PMTCT_ART Already on ART at beginning of current pregnancy 2018 3,517
PMTCT_ART New on ART 2018 7,929
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 11,446
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 216,917
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 11,437
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 1,679
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 9,575
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 56
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 127
PMTCT_STAT By Age (Numerator): 20-24 2018 135,287
PMTCT_STAT By Number of known positives: 20-24 2018 4,697
PMTCT_STAT By Number of new negative: 20-24 2018 202,806
PMTCT_STAT By Number of new positives: 20-24 2018 7,375
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 216,917
PMTCT_STAT_den By Age (Denominator): 20-24 2018 229,139
TB_PREV By Age/Sex (Numerator): <15, Female 2018 853
TB_PREV By Age/Sex (Numerator): <15, Male 2018 1,292
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 7,850
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 11,878
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 21,849
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 21,849
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 43,694
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 1,739
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 2,589
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 15,715
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 23,560
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 43,604
TX_CURR Age/Sex: <1 2018 73
TX_CURR Age/Sex: <1-9 2018 2,312
TX_CURR Age/Sex: 10-14 Female 2018 992
TX_CURR Age/Sex: 10-14 Male 2018 975
TX_CURR Age/Sex: 15-19 Female 2018 956
TX_CURR Age/Sex: 15-19 Male 2018 612
TX_CURR Age/Sex: 20-24 Female 2018 2,224
TX_CURR Age/Sex: 20-24 Male 2018 447
TX_CURR Age/Sex: 25-49 Female 2018 37,633
TX_CURR Age/Sex: 25-49 Male 2018 10,085
TX_CURR Age/Sex: 50+ Female 2018 7,270
TX_CURR Age/Sex: 50+ Male 2018 4,760
TX_CURR Aggregated Age/Sex: <15 Female 2018 6,202
TX_CURR Aggregated Age/Sex: <15 Male 2018 5,945
TX_CURR Aggregated Age/Sex: 15+ Female 2018 144,353
TX_CURR Aggregated Age/Sex: 15+ Male 2018 57,822
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 282,688
TX_CURR Sum of age/sex disaggregates 2018 1,568
TX_CURR Sum of Aggregated Age/Sex <15 2018 12,147
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 202,175
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 214,322
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 1,945
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 1,763
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 31,806
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 14,259
TX_NEW Breastfeeding status 2018 2,872
TX_NEW By Age/Sex: <1 2018 249
TX_NEW By Age/Sex: 1-9 2018 1,028
TX_NEW By Age/Sex: 10-14 Female 2018 239
TX_NEW By Age/Sex: 10-14 Male 2018 179
TX_NEW By Age/Sex: 15-19 Female 2018 371
TX_NEW By Age/Sex: 15-19 Male 2018 161
TX_NEW By Age/Sex: 20-24 Female 2018 1,612
TX_NEW By Age/Sex: 20-24 Male 2018 230
TX_NEW By Age/Sex: 25-49 Female 2018 10,090
TX_NEW By Age/Sex: 25-49 Male 2018 3,769
TX_NEW By Age/Sex: 50+ Female 2018 1,119
TX_NEW By Age/Sex: 50+ Male 2018 805
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 69,672
TX_NEW Pregnancy status 2018 12,721
TX_NEW Sum of Age/Sex disaggregates 2018 18,575
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 49,773
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 211,958
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 189,656
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 5,002
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 553
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 4,864
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 538
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 115,823
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 12,966
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 44,506
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 4,890
TX_PVLS Numerator: Indication: Routine 2018 170,706
TX_PVLS Numerator: Indication: Targeted 2018 18,950
TX_PVLS Unknown Age, Targeted, Male 2018 1
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 5,588
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 633
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 5,442
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 596
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 127,132
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 14,461
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 49,880
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 5,494
TX_PVLS_den Denominator: Indication: Routine 2018 190,740
TX_PVLS_den Denominator: Indication: Targeted 2018 21,185
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,926
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,817
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 69,818
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 17,035
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 92,613
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 108,896
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,416
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3,299
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 82,121
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 20,060
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 268,785
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 6,719
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 242
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 378
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 2,472
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 3,594
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 10,760
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 16,127
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 96,378
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 145,099
TX_TB_den Denominator: By Screen Result: Negative 2018 262,005
TX_TB_den Denominator: By Screen Result: Positive 2018 6,717
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 36
VMMC_CIRC By Age: 10-14 2018 94,334
VMMC_CIRC By Age: 15-19 2018 42,538
VMMC_CIRC By Age: 20-24 2018 22,111
VMMC_CIRC By Age: 25-29 2018 6,726
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 165,709
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 165,709
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 165,709
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 158,983
Cross Cutting Budget Categories and Known Amounts Total: $3,730,000
Key Populations: MSM and TG $100,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: Sex Workers $130,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $1,000,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Human Resources for Health $1,300,000
Food and Nutrition: Policy, Tools, and Service Delivery $200,000
Economic Strengthening $1,000,000